SCTB35 plus Lenalidomide for relapsed or refractory follicular lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 3 interventional study evaluating the safety and efficacy of SCTB35 in combination with Lenalidomide in adults with relapsed or refractory follicular lymphoma. Participants receive SCTB35 injections alongside Rituximab and Lenalidomide to determine if the combo improves disease control. Eligible patients are 18 to 80 years old with confirmed FL, measurable disease, good performance status, and adequate organ function, and who require systemic therapy per GELF criteria. Exclusion includes prior lenalidomide refractoriness and recent lenalidomide exposure. The study is led by Sinocelltech Ltd. with Beijing Cancer Hospital as a participating site.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-80 years old
* Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria
* Relapsed or refractory (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy
* Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion
* A measurable or evaluable disease at the time of enrolment
* ECOG PS 0-2
* Adequate organ function and bone marrow function
* Expected survival ≥ 6 months

Exclusion Criteria:

* Documented refractoriness to lenalidomide.
* Have lenalidomide exposure within 12 months prior to randomization

Where it's running

• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

• CT1182 CAR‑T infusion for adults with relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial tests whether a CT1182 CAR‑T cell infusion is safe and can help adults 18–75 with relapsed or refractory B‑cell non‑Hodgkin lymphoma.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07548697

• NexCAR19 (Talikabtagene Autoleucel) for relapsed or refractory B‑cell leukemias and lymphomas

  This trial will test modified versions of a patient's own T cells (NexCAR19/Talikabtagene Autoleucel) to see if they can control relapsed or refractory B‑cell leukemias and lymphomas in adults.

  Recruiting at 3 sites Phase 2/3 Health Institutes of Turkey · Ankara and 3 other locations · NCT07502118

• MDX2003 for adults with relapsed B‑cell lymphomas

  This trial will test MDX2003 in adults with relapsed or refractory B‑cell lymphomas whose tumors are CD19 or CD20 positive to see if it is safe and can shrink tumors.

  Recruiting at 7 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Richmond, Victoria and 6 other locations · NCT07249905

• Longitudinal multi-center molecular biomarker registry for blood cancers

  This registry will collect serial blood samples and leftover tissue from people with AML or follicular lymphoma to see if molecular biomarkers predict disease course and treatment outcomes.

  Recruiting at 13 sites Tempus AI · Iowa City, Iowa and 12 other locations · NCT07154823

• Safety testing of LTZ-301 in adults with relapsed or refractory B‑cell non-Hodgkin lymphoma

  This trial will test whether LTZ-301 is safe and how it behaves in adults whose B‑cell non-Hodgkin lymphoma has come back or not responded after at least two prior treatments.

  Recruiting at 6 sites Phase 1 LTZ Therapeutics, Inc. · Duarte, California and 5 other locations · NCT07121946

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.